Needham & Company LLC Reiterates “Buy” Rating for Artivion (NYSE:AORT)

Artivion (NYSE:AORT)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports. They presently have a $58.00 price target on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 66.02% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Canaccord Genuity Group reduced their price target on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Stifel Nicolaus set a $55.00 price objective on Artivion in a report on Thursday, March 5th. Finally, Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.47.

Artivion Trading Up 4.4%

Artivion stock traded up $1.49 during trading hours on Tuesday, reaching $34.94. 617,325 shares of the company’s stock traded hands, compared to its average volume of 417,763. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of 174.87 and a beta of 1.63. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The firm’s 50 day moving average is $37.52 and its 200-day moving average is $41.83.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. The company’s quarterly revenue was up 19.2% on a year-over-year basis. On average, analysts predict that Artivion will post 0.37 earnings per share for the current year.

Insider Activity

In related news, insider John E. Davis sold 4,573 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $172,767.94. Following the sale, the insider owned 230,794 shares of the company’s stock, valued at approximately $8,719,397.32. This trade represents a 1.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Lance A. Berry sold 6,316 shares of Artivion stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $238,618.48. Following the transaction, the executive vice president owned 210,827 shares in the company, valued at approximately $7,965,044.06. This represents a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 133,043 shares of company stock valued at $4,977,158. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Artivion

A number of hedge funds have recently modified their holdings of AORT. Royal Bank of Canada increased its stake in Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC lifted its stake in Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after buying an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the period. Creative Planning boosted its holdings in shares of Artivion by 5.6% in the second quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after buying an additional 753 shares during the period. Finally, Invesco Ltd. increased its position in shares of Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.